Edwards Lifesciences Corporation (NYSE:EW) – Equities research analysts at Jefferies Group cut their FY2017 earnings per share estimates for Edwards Lifesciences Corporation in a research note issued on Tuesday, according to Zacks Investment Research. Jefferies Group analyst R. Denhoy now anticipates that the medical research company will post earnings per share of $3.75 for the year, down from their previous forecast of $3.76. Jefferies Group has a “Buy” rating and a $132.00 price objective on the stock.
Edwards Lifesciences Corporation (NYSE:EW) last issued its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.02). The company had revenue of $821.50 million during the quarter, compared to analyst estimates of $833.85 million. Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%. The business’s quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.68 EPS.
TRADEMARK VIOLATION WARNING: This report was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/11/fy2017-eps-estimates-for-edwards-lifesciences-corporation-ew-decreased-by-analyst.html.
Several other research firms also recently issued reports on EW. Zacks Investment Research downgraded shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 17th. SunTrust Banks, Inc. raised their price target on shares of Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a research note on Monday, July 17th. BidaskClub downgraded shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Cowen and Company reissued an “outperform” rating and set a $135.00 target price (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Finally, Barclays PLC lifted their target price on shares of Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 27th. Seven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $125.17.
Edwards Lifesciences Corporation (NYSE EW) traded down $0.93 during mid-day trading on Friday, hitting $103.85. 1,728,200 shares of the stock traded hands, compared to its average volume of 1,650,290. The company has a market capitalization of $22,173.53, a P/E ratio of 29.02, a P/E/G ratio of 1.88 and a beta of 0.46. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.45. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.49 and a quick ratio of 2.76.
Institutional investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. boosted its holdings in Edwards Lifesciences Corporation by 4.6% during the third quarter. Victory Capital Management Inc. now owns 557,773 shares of the medical research company’s stock worth $60,969,000 after purchasing an additional 24,399 shares during the last quarter. Korea Investment CORP raised its position in Edwards Lifesciences Corporation by 144.5% in the third quarter. Korea Investment CORP now owns 355,683 shares of the medical research company’s stock worth $38,880,000 after acquiring an additional 210,200 shares during the period. Raymond James Financial Services Advisors Inc. raised its position in Edwards Lifesciences Corporation by 53.3% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 11,991 shares of the medical research company’s stock worth $1,418,000 after acquiring an additional 4,170 shares during the period. Westpac Banking Corp raised its position in Edwards Lifesciences Corporation by 13.5% in the second quarter. Westpac Banking Corp now owns 14,214 shares of the medical research company’s stock worth $1,681,000 after acquiring an additional 1,691 shares during the period. Finally, Principal Financial Group Inc. raised its position in Edwards Lifesciences Corporation by 41.9% in the second quarter. Principal Financial Group Inc. now owns 465,885 shares of the medical research company’s stock worth $55,086,000 after acquiring an additional 137,643 shares during the period. Institutional investors and hedge funds own 82.32% of the company’s stock.
In related news, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $112.45, for a total transaction of $3,699,605.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Larry L. Wood sold 18,960 shares of the business’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $111.81, for a total transaction of $2,119,917.60. The disclosure for this sale can be found here. Insiders have sold 138,580 shares of company stock valued at $15,039,844 over the last quarter. Corporate insiders own 2.13% of the company’s stock.
Edwards Lifesciences Corporation Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Get a free copy of the Zacks research report on Edwards Lifesciences Corporation (EW)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.